Visual performance in giant cell arteritis (temporal arteritis) after 1 year of therapy

British Journal of Ophthalmology

Volumn 83, Issue 7, 1999, Pages 796-801

  Kupersmith, Mark J ^a,b,e   Langer, Regina ^a   Mitnick, Hal ^b   Spiera, Robert ^c   Spiera, Harry ^c   Richmond, Marjorie ^d   Paget, Stephen ^d  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d HOSPITAL FOR SPECIAL SURGERY   (United States)

^e INN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PREDNISONE;

AGED; ARTICLE; CATARACT; CLINICAL ARTICLE; COLOR VISION; CONTRAST SENSITIVITY; DRUG EFFICACY; FEMALE; GIANT CELL ARTERITIS; GLAUCOMA; HUMAN; MALE; PERIMETRY; PRACTICE GUIDELINE; PRIORITY JOURNAL; VISION; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 0032791125     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.83.7.796     Document Type: Article

References (39)

1. Wagener HP, Hollenhorst RW. Ocular lesions of temporal arteritis. Am J Ophthalmol 1958;45:617-30.
2. Russell RWR. Giant-cell arteritis: a review of 35 cases. Q J Med 1959;28:471-8.
3. Henkind P, Charles NC, Pearson J. Histopathology of ischemic optic neuropathy. Am J Ophthalmol 1970;69:78-90.
4. Wilkinson IMS, Russell R, ROSS W. Arteries of the head and neck in giant cell arteritis. a pathological study to show the pattern of arterial involvement. Arch Neural 1972;27:378-9
5. Grahm E, Holland A, Avery A, et al. Prognosis in giant cell arteritis. BMJ 1981;282:269-71.
6. Delecoeuillerie D, Jolly P, Cohen de Lara A, et al. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (10 year survey of 29 patients). Ann Rheum Dis 1988; 46:733-9.
7. Paget SA, Healey JH, Williams-Russo P, et al. Osteoporosis in steroid-treated patients with polymyalgia rheumatica and temporal arteritis: what is the magnitude and rate over 1 year. Arthritis Rheum 1992;35:S9.
8. Adhikary HP, Sells RA, Basu PK. Ocular complications of systemic steroid after renal transplantation and their association with HLA. Br J Ophthalmol 1982;66:290-1.
9. Godel V, Feiler-Ofry V, Stein R. Systemic steroids and ocular fluid dynamics. I. Analysis of the sample as a whole. Influence of dosage and duration of therapy. Acta Ophthalmol 1972;50:655-63.
10. Godel V, Feiler-Ofry V, Stein R. Systemic steroids and ocular fluid dynamics. II. Systemic versus topical steroids. Acta Ophthalmol 1972;50:664-76.
11. Urban RC, Cotlier E. Corticosteroid-induced cataract. Surv Ophthalmol 1986;31:102-10.
12. Hernandez C, Fernandez B, Ramos P, et al. Giant cell arteritis therapy: methotrexate as a steroid-sparing agent. Arthritis Rheum 1991;34:S73.
13. Van der Veen MJ, Dinant HJ, van Booma-Frankfort C, et al. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis 1996;55:218-23.
14. Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990;33:1122-8
15. Pelli DG, Robson JG, Wilkins AJ. The design of a new letter chart for measuring contrast sensitivity. Clin Vis Sci 1988;2:187-99.
16. The Advanced Glaucoma Intervention Study Investigators. Advanced glaucoma intervention study. 2. Visual field testing scoring and reliability. Ophthalmology 1994;101:1445-55
17. Chylack LT, Leske M, Sperduto R, et al. Lens opacities classification system. Arch Ophthalmol 1988;106:330-4.
18. Leske MC, Chylack LT, Sperduto R, et al. Evaluation of a lens opacities classification system. Arch Ophthalmol 1988; 106:327-9.
19. Kupersmith MJ. Neurovascular neuro-ophthalmology. Heidelberg: Springer-Verlag, 1993:211.
20. Huston KA, Hunder GG, Lie JT, et al. Temporal arteritis: a 25 year epidemiologic, clinical and pathologic study. Ann Intern Med 1978;188:162-7.
21. Hollenhorst RW, Brown JR, Wagener HP, et al. Neurologic aspects of temporal arteritis. Neurology 1960;10:490-8.
22. Liu GT, Glaser JA, Schatz NA, et al. Visual morbidity in giant cell arteritis. Clinical characteristics and prognosis for vision. Ophthalmology 1994;101:1779-85.
23. Calamia KT, Hunder GG. Clinical manifestations of giant cell (temporal) arteritis. Clin Rheum Dis 1980;6:389-403.
24. Rosenfeld SI, Kosmorsky GS, Klingele TG, et al. Treatment of temporal arteritis with ocular involvement. Am J Med 1986;80:143-5.
25. Thystrup J, Knudsen GM, Mogensen AM, et al. Atypical visual loss in giant cell arteritis. Acta Ophthalmol 1994;72: 759-64.
26. Cohen DN. Temporal arteritis: improvement in visual prognsosis and management with repeat biopsies. Trans Am Acad 1973;77:74-85.
27. Aiello PD, Trautmann JC, McPhee TJ, et al. Visual prognosis in giant cell arteritis. Ophthalmology 1993;100:550-5.
28. Slavin M, Margolis AJ. Progressive anterior ischemic optic neuropathy due to giant cell arteritis despite high-dose intravenous corticosteroids. Arch Ophthalmol 1988;106: 167.
29. Beevers DG, Harpur JE, Turk KAD. Giant cell arteritis: the need for prolonged treatment. J Chrom J Dis 1973;26:571-84.
30. Sorensen PS, Lorenzen I. [Giant-cell arteritis, temporal arteritis, and polymyalgia rheumatica.] [Danish] Ugescrift for Laeger 1975;131:1135-41.
31. Myles AB, Perera T, Ridley MG. Prevention of blindness in giant cell arteritis by cortciosteroid treatment. Br J Rheumatol 1992;31:103-5.
32. Meli B. Landau K, Gloor BP. Die rucken der riesenzellarteriitis aus ophthalmologischer sicht. Schweiz Med Wochenschr 1996;126:1821-8.
33. Healey LA, Wilske KR. Manifestations of giant cell arteritis. Med Clin NA 1977;61:261-70.
34. Blumberg S, Giansiracusa DF, Docken WP, et al. Recurrence of temporal arteritis. clinical recurrence nine years after initial illness. JAMA 1980;244:1713-14.
35. Cullen JF. Temporal arteritis occurrences of ocular complications seven years after diagnosis. Br J Ophthalmol 1972;56:584-8.
36. Hamilton CR Jr, Shelley WM, Tumulty PA. Giant cell arteritis: including temporal arteritis and polymyalgia rheumatica. Medicine 1971;50:l-27.
37. Kyle V, Hazelamn BL. Treatment of polymyalgia rheumatica and giant cell arteritis. I. steroid regimens in the first two months. Ann Rheum Dis 1989;48:658-61.
38. Faarvang KL, Pontoppidan Thyssen E. Giant cell arteritis: loss of vision during corticosteroid therapy. J Intern Med 1989;225:215-16.
39. Gumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997;337:8-14.